



EHRA
European Heart
Rhythm Association



Application for the following position in the EHRA Board: **Nominating Committee member**

1. Your Identity

Title: Professor/Dr.

Family Name(s): Natale

First Name(s): Andrea

Birth Date: October 15, 1960

Institute/Organisation: University of Tor Vergata, Rome, Italy and Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX, USA

Department: Cardiology, Electrophysiology

Address: 3000 N. I-35, Suite 720; Austin, TX, USA

Post Code/Zip: 78705



2. General Curriculum Vitae (300 words max)- Please add your H index and top 10 publications in the last 5 years

Andrea Natale, M.D., F.H.R.S, F.A.C.C., F.E.S.C., F.A.P.H.R.S.

Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Austin, Texas

Chair of the Cardiac Electrophysiology Operations Council, Cardiac & Vascular Leadership Council

Professor, department of Biomedicine and Prevention, Division of Cardiology, University of Tor Vergata, Rome, Italy

H-index: 143

Publications:

1. Pulsed Field Ablation to Treat Paroxysmal Atrial Fibrillation: Safety and Effectiveness in the AdmIRE Pivotal Trial. *Circulation*. 2024 Oct 8;150(15):1174-1186
2. Early versus late atrial fibrillation recurrence after pulsed field ablation: insights from the admIRE trial. *Europace*. 2025 Feb 5;27(2):euaf007.
3. Pulsed Field Ablation for Persistent Atrial Fibrillation: 1-Year Results of ADVANTAGE AF. *J Am Coll Cardiol*. 2025 May 6;85(17):1664-1678.
4. Comparison of left atrial appendage closure and oral anti-coagulation after catheter ablation for atrial fibrillation: Concomitant and sequential cohorts of the OPTION randomized controlled trial. *Heart Rhythm*. 2025 Oct;22(10):2585-2594
5. Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2. *Circulation*. 2025 Jul 8;152(1):27-40
6. Dynamic data-driven management of atrial fibrillation with implantable cardiac monitors: The MONITOR AF study. *Heart Rhythm*. 2025 Jan 16:S1547-5271(25)00025-6
7. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. *N Engl J Med*. 2023 Nov 2;389(18):1660-1671
8. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. *J Arrhythm*. 2024 Oct 6;40(6):1217-1354
9. Catheter ablation for atrial fibrillation: indications and future perspective. *Eur Heart J*. 2024 Nov 7;45(41):4383-4398
10. Prevalence, timing, and impact of early recurrence of atrial tachyarrhythmias after pulsed field ablation: A secondary analysis of the PULSED AF trial. *Heart Rhythm*. 2025 Apr;22(4):884-890





3. Describe previous experience(s) within EHRA, ESC or your National Cardiac Society

EHRA/ESC:

FESC with the European Society of Cardiology: 2010 – present

Deputy Editor, Europace (Jan 2023 – Present)

HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation Writing Group: 2007, 2012, 2017, 2024, current (to be published in 2026)

Invited faculty and abstract grader, EHRA/ESC: 2009-present

Pioneer in EP Award from EHRA: 2020

National Cardiac Society:

Professional membership:

FACC with the American College of Cardiology – 2006 – present

American Heart Association – Jul 2003 – present

FHRS with the Heart Rhythm Society – 2006 – present

Heart Rhythm Society Member – 2004 – present

Member of the ACC Cardiovascular Management Section Leadership Council (Apr 1, 2020 – Apr 1, 2023)

Prominent Committee activities:

ACC Cardiovascular Management Section Leadership Council (April 1, 2020 – April 1 – 2023)

NCDR EP Registry Steering Subcommittee Member (4/1/18 to 3/31/21)

NCDR AF Ablation Steering Subcommittee Member (2018-21)

Council on Clinical Cardiology and Council on Epidemiology and Prevention (AHA)

Heart Rhythm Society Board of Trustees. (May 2011 – May 2014)

HRS Board Liaison to the CME Compliance Subcommittee (Education Committee) (May 10, 2013 – 2014)

HRS PFA Registry Task Force advisor and HRA executive committee member: 2025



4. Why are you motivated to join the EHRA Executive Board (250 words max)?

Here are the causes that motivate me to join the EHRA executive board.

First, I would very much like to be a part of the advocacy group that promotes cardiovascular policies that are favourable for patients, physicians and the allied health personnel. Additionally, the members can play an active role in raising awareness among patients and their caregivers, of the growing burden of atrial fibrillation (AF) and the risk of AF-related stroke, heart failure and premature death. Moreover, the advocacy group can influence the regulatory system to support innovations in techniques and technologies enhancing the safety and efficacy of electrophysiology (EP) procedures.

Another rewarding aspect of being a board member would be to be engaged in promoting and driving innovations in digital health-data collection in a common cardiovascular registry that can be freely accessed by member organizations and exchanged among researchers and healthcare providers as well as utilized for evidence-based decision-making. This would, undoubtedly ensure the transparency and fairness of the system.

The privilege as a board member, to contribute to increased awareness in the AF community regarding early therapeutic interventions to reduce the risk of stroke, heart failure and death also seems very rewarding.

Lastly, I believe, as executive members, we would be able to elevate the visibility of EHRA as a prominent platform for EP research and innovations by inviting experts from around the world to attend the congress, present their work and mentor fellows and young cardiologists and electrophysiologists.



5. How will you combine your EHRA position with your daily clinical/research workload?

Please note that we expect you to:

- Have an active career at the time of taking office
- Be on clinical practice (for at least 30%) at the time of application

I am fully aware of the time demand of this position and confident that I will be able to accommodate this additional responsibility by making time for it. I will dedicate at least 10% of my time (4-5 hours per week) and additional hours during the weekends for the assigned activities as a board member.



6. Please list your conflicts of interest

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
Consultancy from the following companies:
 - Abbott: <10K/year
 - Biosense Webster: 10-50K/ year
 - Biotronik: <10K/year
 - Boston Scientific: 10-50K/year
 - Field Medical: <10K/year
 - iRhythm: <10K/year
 - Medtronic: <10K/year
 - Pulse Bioscience: <10K/year

- Receipts of royalties for intellectual property: **NONE**
 - Company (one company):
 - Product or therapeutic area:
 - <10 K€/ year 10-50 K€/year 50-100 K€/year >100 >K€/year

Position of influence declaration:

- Direct substantial shareholding or direct financial interest in healthcare, media, education companies or companies in relationship (suppliers or in competition with ESC or in contradiction with ESC mission)
- Employment in healthcare institution (part time or full time)
- Membership or affiliation to political/pressure group associations related to the field of cardiology
- Any potential interest related to the position applied for
- **Nothing to declare**
- More info at <https://www.escardio.org/The-ESC/About/Policies/esc-declaration-and-management-of-conflict-of-interest-policy>